The role of co-infections and secondary infections in patients with COVID-19

dc.contributor.authorFeldman, Charles
dc.contributor.authorAnderson, Ronald
dc.date.accessioned2022-05-17T08:57:15Z
dc.date.available2022-05-17T08:57:15Z
dc.date.issued2021-04
dc.description.abstractBACKGROUND: It has been recognised for a considerable time-period, that viral respiratory infections predispose patients to bacterial infections, and that these co-infections have a worse outcome than either infection on its own. However, it is still unclear what exact roles co-infections and/or superinfections play in patients with COVID-19 infection. MAIN BODY: This was an extensive review of the current literature regarding co-infections and superinfections in patients with SARS-CoV-2 infection. The definitions used were those of the Centers for Disease Control and Prevention (US), which defines coinfection as one occurring concurrently with the initial infection, while superinfections are those infections that follow on a previous infection, especially when caused by microorganisms that are resistant, or have become resistant, to the antibiotics used earlier. Some researchers have envisioned three potential scenarios of bacterial/SARS-CoV-2 co-infection; namely, secondary SARS-CoV-2 infection following bacterial infection or colonisation, combined viral/bacterial pneumonia, or secondary bacterial superinfection following SARSCoV-2. There are a myriad of published articles ranging from letters to the editor to systematic reviews and metaanalyses describing varying ranges of co-infection and/or superinfection in patients with COVID-19. The concomitant infections described included other respiratory viruses, bacteria, including mycobacteria, fungi, as well as other, more unusual, pathogens. However, as will be seen in this review, there is often not a clear distinction made in the literature as to what the authors are referring to, whether true concomitant/co-infections or superinfections. In addition, possible mechanisms of the interactions between viral infections, including SARS-CoV-2, and other infections, particularly bacterial infections are discussed further. Lastly, the impact of these co-infections and superinfections in the severity of COVID-19 infections and their outcome is also described. CONCLUSION: The current review describes varying rates of co-infections and/or superinfections in patients with COVID-19 infections, although often a clear distinction between the two is not clear in the literature. When they occur, these infections appear to be associated with both severity of COVID-19 as well as poorer outcomes.en_US
dc.description.departmentImmunologyen_US
dc.description.librarianpm2022en_US
dc.description.urihttps://pneumonia.biomedcentral.comen_US
dc.identifier.citationFeldman, C., & Anderson, R. (2021). The role of co-infections and secondary infections in patients with COVID-19. Pneumonia, 13(1), 5. https://doi.org/10.1186/s41479-021-00083-w.en_US
dc.identifier.issn2200-6133 (online)
dc.identifier.other10.1186/s41479-021-00083-w
dc.identifier.urihttps://repository.up.ac.za/handle/2263/85245
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.subjectBacteriaen_US
dc.subjectCo-infectionsen_US
dc.subjectFungal infectionsen_US
dc.subjectOutcomeen_US
dc.subjectSeverityen_US
dc.subjectSuperinfectionsen_US
dc.subjectVirusesen_US
dc.subjectCOVID-19 pandemicen_US
dc.subjectCoronavirus disease 2019 (COVID-19)en_US
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)en_US
dc.subjectTuberculosis (TB)en_US
dc.titleThe role of co-infections and secondary infections in patients with COVID-19en_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Feldman_Role_2021.pdf
Size:
783.7 KB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: